IMMUNOCELLULAR THERAPEUTICS's ticker is IMUC and the CUSIP is 452536105. A total of 32 filers reported holding IMMUNOCELLULAR THERAPEUTICS in Q1 2015. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $6,000 | -66.7% | 51,768 | -33.1% | 0.00% | – |
| Q2 2016 | $18,000 | +125.0% | 77,361 | +168.5% | 0.00% | – |
| Q1 2016 | $8,000 | +14.3% | 28,813 | +51.6% | 0.00% | – |
| Q4 2015 | $7,000 | -12.5% | 19,012 | 0.0% | 0.00% | – |
| Q3 2015 | $8,000 | -27.3% | 19,012 | -21.8% | 0.00% | – |
| Q2 2015 | $11,000 | +22.2% | 24,301 | +26.9% | 0.00% | – |
| Q1 2015 | $9,000 | -35.7% | 19,150 | +0.5% | 0.00% | – |
| Q4 2014 | $14,000 | -17.6% | 19,046 | -0.1% | 0.00% | – |
| Q3 2014 | $17,000 | -19.0% | 19,058 | -0.2% | 0.00% | – |
| Q2 2014 | $21,000 | -16.0% | 19,098 | -5.3% | 0.00% | – |
| Q1 2014 | $25,000 | -88.9% | 20,159 | -91.7% | 0.00% | – |
| Q4 2013 | $225,000 | -62.4% | 243,376 | +4.6% | 0.00% | – |
| Q3 2013 | $598,000 | -36.2% | 232,729 | -51.8% | 0.00% | – |
| Q2 2013 | $938,000 | +23.4% | 483,278 | +22.1% | 0.00% | – |
| Q4 2012 | $760,000 | +55.4% | 395,729 | +127.6% | 0.00% | – |
| Q3 2012 | $489,000 | -24.2% | 173,900 | +1.1% | 0.00% | – |
| Q2 2012 | $645,000 | – | 172,068 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 4,443,914 | $1,579,000 | 0.09% |
| CHELSEA COUNSEL CO | 28,000 | $10,000 | 0.00% |
| Ifrah Financial Services, Inc. | 18,500 | $7,000 | 0.00% |
| Gerstein Fisher | 13,000 | $5,000 | 0.00% |
| Renaissance Technologies | 1,407,200 | $500,000 | 0.00% |
| CITIGROUP INC | 31,700 | $11,000 | 0.00% |
| GOLDMAN SACHS GROUP INC | 19,012 | $7,000 | 0.00% |
| Catamount Wealth Management | 1,000 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 439,847 | $156,000 | 0.00% |
| GUGGENHEIM CAPITAL LLC | 19,166 | $7,000 | 0.00% |